- Neovasc Inc. (NVCN) has shared positive clinical data regarding its Reducer treatment for angina patients with non-obstructive coronary artery disease
- The Reducer is a device designed to alter blood flow within the heart and increase the perfusion of oxygenated blood to certain areas of the heart muscle
- Results showed the coronary microvascular flow parameters, symptoms of angina, functional capacity, and quality of life all improved
- Neovasc will move its focus to the Reducer therapy and the ongoing clinical trial
- Neovasc Inc. (NVCN) is up 1.66 per cent, trading at $8.58 per share at 4:08 p.m. ET
Neovasc (NVCN) has shared positive clinical data regarding its Reducer treatment for angina patients with non-obstructive coronary artery disease (ANOCA).
The Reducer is a device designed to alter blood flow within the heart and increase the perfusion of oxygenated blood to certain areas of the heart muscle, which may provide relief of angina symptoms.
According to the company, data collected on the first 11 ANOCA patients, majority female, for a clinical trial in Israel evaluated the impact of the Reducer on those with microvascular disease. It also looked at the treatment’s effect on angina symptoms using objective measures of blood flow in the heart before and after Reducer implantation.
Results suggested improvements in objective measures of blood flow in the system containing small vessels which are not cooperative with stenting or bypass surgery. After an invasive physiological assessment, results showed the coronary microvascular flow parameters, symptoms of angina, functional capacity, and quality of life all improved.
Fred Colen, President and CEO of Neovasc, commented,
“This is intriguing early clinical data that could lead to Reducer being used as a treatment option for a patient population at least as large as our current target market and at a much earlier stage in the patient treatment cycle.”
Neovasc stated it will move its focus to the Reducer therapy and the ongoing clinical trial. However, the company will continue to work on its mitral and tricuspid valve intellectual property portfolio and is committed to Tiara patient surveillance and clinical trial follow-up.
Neovasc Inc. (NVCN) is up 1.66 per cent, trading at $8.58 per share at 4:08 p.m. ET.
